CSTL
Castle Biosciences Inc
$23.72
-0.84 (-3.42%)
At close · Jul 10
Market Cap
$719.43M
Shares
30,329,952
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.72
Open$24.55
Day$23.36–24.67
52W$14.59–44.28
Avg vol 30d334K
Short int1.5M · 4.9% float · 3.2d
Short vol45%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
+9%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
−42%
trailing
YTD return
−39%
this year
Relative strength
−51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $29 — 200d above 50d
Institutional flow
Distributing
5 of 186 funds reported for Jun 30 · net -173.9K sh shares
Insider flow
Distributing
Net -$611.8K over 90 days · 100% sells
Short interest
Rising
4.92% of float · ▲ +0.5% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
186 holders — mid 3-yr range
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
Gross margin
15%
expanding
EPS growth
−234%
Y/Y
Free cash flow
$28.3M
Balance sheet
$106.7M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Total revenue
· full-year 2026
Maintained
$345M – $355M
prior FY $344.23M
midpoint +1.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $22 › 200d $29 — 200d above 50d
Institutional flow
Distributing
5 of 186 funds reported for Jun 30 · net -173.9K sh shares
Insider flow
Distributing
Net -$611.8K over 90 days · 100% sells
Short interest
Rising
4.92% of float · ▲ +0.5% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
186 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $15
Now $24 · 31%
52-wk high $44
vs 200-day avg -17%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Gross Margin non-GAAP | 76% | Q1 2026 | — |
|
|
|||
| DecisionDx-Melanoma test reports delivered | 10,021 | Q1 2026 | — |
|
|
|||
| DecisionDx-SCC test reports delivered | 3,702 | Q1 2026 | — |
|
|
|||
| DecisionDx-UM test reports delivered | 492 | Q1 2026 | — |
|
|
|||
| MyPath Melanoma test reports delivered | 973 | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | -$5.1M | Q1 2026 call | — |
| Advanced ADTx orders | 650 | Q1 2026 call | — |
| cash, cash equivalents, and marketable securities | $261.7M | as of 03/31/2026 call | — |
| DecisionDx-Melanoma test reports | 10,021 | Q1 2026 call | — |
| DecisionDx-Melanoma year-over-year growth | 16% | Q1 2026 call | — |
| net cash used in investing activities | -$25.8M | Q1 2026 call | — |
| net cash used in operating activities | -$22.1M | Q1 2026 call | — |
| test report volumes year-over-year growth for core revenue drivers | 36% | Q1 2026 call | — |
| TissueCypher test reports | 11,745 | Q1 2026 call | — |
| TissueCypher year-over-year growth | 58% | Q1 2026 call | — |
| IDgenetix test reports delivered | 3,605 | Twelve Months Ended Dec. 31, 2025 | — |
| DecisionDx-Melanoma test reports delivered in 2025 | 39,083 | year ended December 31, 2025 | — |
| DecisionDx-Melanoma test reports delivered in the quarter | 10,022 | the fourth quarter of 2025 | — |
| DecisionDx-SCC test reports delivered in 2025 | 17,294 | year ended December 31, 2025 | — |
| DecisionDx-SCC test reports delivered in the quarter | 3,971 | the fourth quarter of 2025 | — |
| DecisionDx-UM test reports delivered in 2025 | 1,769 | year ended December 31, 2025 | — |
| DecisionDx-UM test reports delivered in the quarter | 395 | the fourth quarter of 2025 | — |
| IDgenetix test reports delivered in 2025 | 3,605 | year ended December 31, 2025 | — |
| MyPath Melanoma test reports delivered in 2025 | 4,288 | year ended December 31, 2025 | — |
| MyPath Melanoma test reports delivered in the quarter | 1,045 | the fourth quarter of 2025 | — |
| TissueCypher Barrett's Esophagus test reports delivered in 2025 | 39,014 | year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSTL
this stock
Castle Biosciences Inc
|
$719.43M | -39.0% | +3.7% | — | 4.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.88B | -12.7% | +8.5% | 38.4 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.66B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSTL | -1.6% | +12.5% | -41.8% | -0.6% | -39.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -3.0% | +8.5% | -50.9% | -1.7% | -49.7% |